Nykredit A S Invests $92.32 Million in Merck & Co., Inc. $MRK

Key Points

• Nykredit A/S acquired 718,471 Merck shares in the second quarter, valued at approximately $92.3 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Merck exceeded quarterly earnings and revenue expectations, reporting adjusted EPS of $(0.13) and revenue of $16.61 billion, while revenue increased 5.1% year over year.
• The company declared a quarterly dividend of $0.85 per share, equating to an annualized $3.40 payout and a 2.3% yield. Analysts maintain a “Moderate Buy” consensus, though insiders sold nearly $30 million of shares over the past 90 days.

Nykredit A S purchased a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 718,471 shares of the company's stock, valued at approximately $92,324,000.

Several other institutional investors have also recently added to or reduced their stakes in MRK. BlackRock Inc. lifted its position in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. Wellington Management Group LLP raised its stake in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock valued at $11,083,033,000 after buying an additional 1,934,312 shares in the last quarter. Geode Capital Management LLC raised its stake in Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock valued at $6,307,572,000 after buying an additional 249,110 shares in the last quarter. Norges Bank bought a new position in Merck & Co., Inc. during the 4th quarter worth approximately $3,997,933,000. Finally, Bank of America Corp DE lifted its holdings in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after buying an additional 2,919,780 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Williams sold 52,847 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares of the company's stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 in the last ninety days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $147.31 on Friday. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $156.92. The company has a market cap of $363.45 billion, a price-to-earnings ratio of 117.85, a price-to-earnings-growth ratio of 6.31 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The firm has a fifty day moving average of $137.99 and a 200-day moving average of $125.05.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Analyst Ratings Changes

Several brokerages have recently commented on MRK. Argus lifted their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. Wolfe Research raised their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 25th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. Weiss Ratings upgraded shares of Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 25th. Finally, Barclays boosted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Seventeen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $154.24.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck outperformed the broader market in the latest session, reflecting continued investor momentum and demand for the pharmaceutical company’s shares. Merck Outperforms Broader Market
• Positive Sentiment: Positive Phase 3 data has helped Merck beat the market in 2026, while its dividend—an annualized payout of approximately $3.40—offers a yield above 2.3%, supporting the stock’s appeal to income-oriented investors. Merck Dividend and Market Performance
• Positive Sentiment: Merck is pursuing opportunities to extend Keytruda-related research through commercial orbital laboratories. Although still experimental, the initiative could create new insights for oncology research if regulatory and logistics hurdles are resolved. Keytruda Space Research
• Positive Sentiment: Analysts and investors are increasingly focused on Merck’s efforts to build a stronger portfolio beyond Keytruda, including its roughly $70 billion pipeline and potential oncology partnerships. Merck’s Pipeline Beyond Keytruda
• Neutral Sentiment: Brokerages have set an average price target of $151.32, implying limited additional upside from recent levels and signaling measured rather than aggressive optimism. Merck Price Target
• Neutral Sentiment: RBC Capital maintained a Hold rating, suggesting the company’s growth prospects are balanced by valuation and execution risks. RBC Maintains Hold Rating
• Neutral Sentiment: Unusually high options volume indicates increased trading interest, but it does not by itself establish a bullish or bearish direction. Merck Options Volume
• Negative Sentiment: Merck’s premium valuation leaves less room for disappointment, while the market remains concerned about the eventual loss of Keytruda exclusivity and whether the pipeline can replace that franchise’s earnings contribution. Merck Pipeline Valuation Analysis

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.